DEMYSTIFYING THE VALUE OF AI FOR RARE DISEASE SCIENCE AND TREATMENT
Artificial intelligence is being heralded as the next revolution. For rare disease, that revolution is already beginning: artificial intelligence is accelerating patient diagnosis, target discovery, drug discovery, and clinical care through efforts by academic researchers, industry, and patient advocacy groups.
co-produced by:
Presented by:
OUR SPEAKERS
JOHN REYNDERS
CARRIE BURKE
VP, Data Sciences, Genomics, and Bioinformatics
Alexion Pharmaceuticals
VP, Business Development and Partnerships,
Clinithink
RANJEET ALEXIS
Investment Director
Intel Capital
DAVE BJORK
CHARLOTTE HOBBS
Director of Community Relations,
FRAXA Research Foundation
VP Research & Clinical Management,
Rady Children’s Institute for Genomic Medicine
TIM GULLIAMS
CEO & Co-Founder,
Healx
Tuesday, January 14, 4:30-5:15 pm
Hilton San Francisco Union Square
MODERATOR
All Rights Reserved. Forward ® 2020
EBD Group Inc., 3150 Pio Pico Drive, Suite 201, Carlsbad, CA, 92008